SkinHealth Systems Inc. (SKIN) Guidance & Earnings Results

On 2026-08-06 SkinHealth Systems Inc. lowered guidance: "Q3 2026 net sales $65-70M, adjusted EBITDA $5-7M; FY2026 net sales $280-290M, adjusted EBITDA…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

SKINSkinHealth Systems Inc.Follow SKIN — free

Household & Personal Products · Consumer Defensive

—

Price chart with a free account

Market cap: —
P/E TTM: —
Dividend yield: —
52-week: —
Next earnings: 4 Nov, in 11 days

What management guided

each earnings 8-K · figures checked against the filing text

Release	Direction	What they said
6 Aug 26	Lowered	Q3 2026 net sales $65-70M, adjusted EBITDA $5-7M; FY2026 net sales $280-290M, adjusted EBITDA $39-46M · full year
7 May 26	Lowered	FY26 net sales $280-295M (prior not stated); Q2 net sales $72-77M; FY26 adjusted EBITDA $35-45M; Q2 adjusted EBITDA $11-13M · full year
12 Mar 26	Mixed	Q1 2026 net sales $63-68M; Q1 2026 Adj. EBITDA $3.5-5.5M; FY2026 net sales $285-305M; FY2026 Adj. EBITDA $35-45M · full year
6 Nov 25	Raised	FY2025 net sales $293-300M; Adjusted EBITDA $37-39M · full year
7 Aug 25	Raised	FY25 net sales $285-300M; Adjusted EBITDA $27-35M. Q3 net sales $65-70M; Adjusted EBITDA $2-4M. · full year

SkinHealth Systems Inc. — questions

What guidance did SkinHealth Systems Inc. give?: On 2026-08-06: "Q3 2026 net sales $65-70M, adjusted EBITDA $5-7M; FY2026 net sales $280-290M, adjusted EBITDA $39-46M"
When does SkinHealth Systems Inc. report earnings?: SkinHealth Systems Inc.'s next earnings report is expected on 2026-11-04.

Every figure on this page comes from SkinHealth Systems Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.